https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidem

Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stake

Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript

On Thursday, Co-Diagnostics (NASDAQ:CODX) discussed second-quarter financial results during its earn

Co-Diagnostics (OTC:CODX) reported quarterly losses of $(1.46) per share which beat the analyst cons

Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expan

Submission includes a concurrent CLIA Waiver by Application for use of the test on the Co-Dx PCR Pro

Merck and Wellcome-backed Hilleman will manufacture Bundibugyo Ebola vaccine doses for clinical tria

SALT LAKE CITY, July 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the C

Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's r

Company also completes proof of concept for the first blood-borne test for Ebola on Co-Dx PCR Pro ®

Co-Diagnostics advances its Ebola testing capabilities, sending Bundibugyo virus test kits for evalu

Forte Biosciences shares rose 38.9% to $76.10 in pre-market trading after argenx SE announced plans

PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India SALT LAKE CITY, July

Co-Diagnostics' India joint venture CoSara has started clinical studies for its rapid TB PCR tes

SALT LAKE CITY, July 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the C

Invited by the Stop TB Partnership and the Global Fund to participate as a manufacturer partner Work

More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 2

Co-Diagnostics completed clinical and analytical studies for its PCR Flu A/B & RSV test and plan

Expansion coincides with Co-Dx webinar for prospective mosquito abatement district customers in hono

Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnosti

Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro® and expanding menu

Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro ® and expanding men

https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/

Dual-assay strategy designed to support outbreak response and surveillance efforts in affected regio

Dual-assay strategy designed to support outbreak response and surveillance efforts in affected regio

A structural shift is underway in the biodefense landscape. The declaration of a Public Health Emerg

 Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnost

Joint development strategy has been developed to address international deployment requirements if cu

Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, COD

Co-Diagnostics shares jump 28% following a $3.0M private placement and key progress on its Bundibugy

SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx", or the "C

Recent pathogens illustrate need for improved situational awareness capabilities, such as those prov

https://www.cdc.gov/ebola/situation-summary/index.html

Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Transcript

Advancing Global Commercialization Through CoSara Regulatory Progress and Regional Expansion Executi